{"created":"2024-04-11T05:46:20.501547+00:00","id":2000376,"links":{},"metadata":{"_buckets":{"deposit":"cb680e9b-08f1-4a79-a573-808d9392a333"},"_deposit":{"created_by":11,"id":"2000376","owner":"11","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"2000376"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:02000376","sets":["13:40"]},"author_link":["4213"],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2024-03-24"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Introduction: Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established as first-line treatment, but they have not been confirmed as second-line treatment after FFX. The aim of this study was to evaluate the safety and efficacy of GnP as second-line therapy after FFX in patients with unresectable pancreatic cancer.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Methods: Twenty-five patients with unresectable pancreatic cancer were enrolled. The patients were treated with GnP after FFX between September 2015 and September 2019. Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events were evaluated.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results: The response rate, disease control rate, median PFS, and median OS were 12%, 96%, 5.3 months, and 15.6 months, respectively. The common grade 3 or 4 adverse events were neutropenia (76%) and anemia (16%).","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions: GnP after FOLFIRINOX is expected to be one of the second-line recommendations for patients with unresectable pancreatic cancer.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第855号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1159/000517244","subitem_relation_type_select":"DOI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"34284397","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 S. Karger AG, Basel","subitem_rights_language":"eo"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAlternatives":[{"creatorAlternative":"羽床, 琴音","creatorAlternativeLang":"ja"},{"creatorAlternative":"ハユカ, コトネ","creatorAlternativeLang":"ja-Kana"},{"creatorAlternative":"Hayuka, Kotone","creatorAlternativeLang":"en"}],"creatorNames":[{"creatorName":"野村, 琴音","creatorNameLang":"ja"},{"creatorName":"ノムラ, コトネ","creatorNameLang":"ja-Kana"},{"creatorName":"Nomura, Kotone","creatorNameLang":"en"}],"familyNames":[{"familyName":"野村","familyNameLang":"ja"},{"familyName":"ノムラ","familyNameLang":"ja-Kana"},{"familyName":"Nomura","familyNameLang":"en"}],"givenNames":[{"givenName":"琴音","givenNameLang":"ja"},{"givenName":"コトネ","givenNameLang":"ja-Kana"},{"givenName":"Kotone","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4213","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-04-11"}],"filename":"Med_A855.pdf","filesize":[{"value":"1.9 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/2000376/files/Med_A855.pdf"},"version_id":"0aaf9327-93ec-46c5-b789-5db0f325b5f2"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-04-11"}],"filename":"Med_A855_abstract.pdf","filesize":[{"value":"78 KB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/2000376/files/Med_A855_abstract.pdf"},"version_id":"0cfea9e8-cbcb-4c53-9304-1916560f73ba"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-04-11"}],"filename":"Med_A855_result.pdf","filesize":[{"value":"79 KB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/2000376/files/Med_A855_result.pdf"},"version_id":"6170dfea-718c-4053-80b4-f938cf0d18b1"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Pancreatic cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Gemcitabine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nab-paclitaxel","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"FOLFIRINOX","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Second-line treatment","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Gemcitabine plus nab-paclitaxel as second-line chemotherapy following FOLFIRINOX in patients with unresectable pancreatic cancer : A single-institution, retrospective analysis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Gemcitabine plus nab-paclitaxel as second-line chemotherapy following FOLFIRINOX in patients with unresectable pancreatic cancer : A single-institution, retrospective analysis","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-04-11"},"publish_date":"2024-04-11","publish_status":"0","recid":"2000376","relation_version_is_last":true,"title":["Gemcitabine plus nab-paclitaxel as second-line chemotherapy following FOLFIRINOX in patients with unresectable pancreatic cancer : A single-institution, retrospective analysis"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2024-10-31T08:01:44.567771+00:00"}